drugset / Trial / NCT04764474

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

NCT04764474

Phase 1 Terminated 46 enrolled Hutchmed
NaSingle-groupOpen-labelTreatment

Summary

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.

Timeline

Start
2021-04-12
Primary completion
2025-01-15
Completion
2025-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject RANOSIDENIB Small molecule Oral

Indications

No indication recorded.